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Ploidy represents the number of chromosome sets in a cell.  Whereas gametes have 
a haploid genome (n), most mammalian cells have diploid genomes (2n).  The diploid 
status of most cells correlates to the number of probable alleles for each autosomal 
gene and makes it difficult to target these genes via mutagenesis techniques.  Here 
we describe a seven-week protocol for the derivation of mouse haploid embryonic 
stem cells (hESC) from female gametes that also describes how to maintain the cells 
once derived.  We also detail additional procedures that can be used with cell lines 
obtained from the mouse Haplobank, a biobank of over 100,000 individual mouse 
hESC lines with targeted mutations in 16,970 genes.  hESC can spontaneously 
diploidize and can be maintained both in haploid and diploid states.  Mouse hESC are 
genomically and karyotypically stable, are innately immortal, isogenic and can be 
derived in an array of differentiated cell types, and are thus highly amenable for genetic 




The packing and organization of genomes into chromosomes is central to the 
maintenance and transmission of genes during evolution1.  In eukaryotes, ploidy 
(defined as the number of chromosome sets, n, of each cell) can range from a haploid 
genome n=1 chromosome in the male of the Jack-jumper ant (Myrmecia pilosula)2 to 
a staggering ~1900n=~15,600 chromosomes (29,64 x 106 chromosomes) in the 
ciliated protozoan Oxytricha trifallax3.  However, within mammals, the large majority 
of species maintain a diploid (2n) organization for most somatic cells and haploid (n) 
for gametes; an exception being made by the tetraploid vizcacha rat Tympanoctomys 
barrerae4.  The somatic/diploid and germline/haploid configuration is beneficial and 
enables genetic variation to be increased through sexual reproduction5, whilst 
conferring protection from deleterious mutations in the long-lived somatic tissues both 
by allowing the presence of back-up alleles as well as providing a template for DNA 
damage repair6.  Thus, to maintain normal physiology, mammalian cells have 
developed mechanisms that act throughout the cell cycle to prevent the occurrence of 
cells with abnormal chromosome numbers (aneuploid or polyploid)7 as these are a 
hallmark of genomic instability and oncogenic transformation8. 
 
Most somatic cells maintain their diploid chromosome number through mitotic division, 
although non-oncogenic mosaic polyploidy can happen in selected tissues during 
development (e.g. placenta) or in adult life (e.g. liver, muscle or brain)9.  In contrast, 
the germ cells (oocytes or sperm) are terminally differentiated cells incapable of mitotic 
self-renewal in vivo.  While methods of derivation and maintenance in cell culture for 
somatic cells are very well established, the derivation and culture of oocyte derived 
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haploid embryonic stem cells has only recently been achieved10-13 (also see preview 
by Sagy and Benvenisti14).  Here, we detail an experimental protocol for the derivation, 
maintenance and use of haploid mouse embryonic stem cells (hESCs). 
 
Development and applications of the protocol 
The haploid budding yeast (Saccharomyces cerevisiae) has been used for a long time 
as a model organism for genetic experiments as its genome can be easily manipulated 
so-as-to generate insertion/deletions, targeted or random-mutagenesis15. 
 
In vivo, mouse N-Ethyl-N-Nitrosourea (ENU) mutagenesis was until recently the only 
method used to perform random mutagenesis screens in mammalian haploid cells16.  
Although very informative, these screens require extensive resources, space and time 
for phenotypic mutants of interest to be identified.  More recently, the discovery of 
KBM7, a near-haploid leukemic cancer cell line17,18, and its further engineering to 
remove one extra copy of chromosome 819 and parts of chromosome 1520 created the 
HAP1 cell line, representing the first human cell line with a haploid-genome to be 
propagated in culture.  Limitations of the HAP1 cells relate to their transformed nature 
and presence of various genomic alterations, including the BCR-ABL1 translocation, 
confounding some studies which aim to understand physiologic genetic pathways in 
normal cells. 
 
In vitro activation of oocytes for parthenogenetic embryogenesis and later generation 
of haploid ESCs was initially done in the 1920’s by Gregory Pincus, who observed that 
some unfertilized rabbit oocytes could spontaneously undergo variable degrees of 
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development that were indistinguishable morphologically from the development of 
fertilized oocytes21.  Subsequent work expanded on these methods in mouse models 
and showed that exposing a mouse oocyte to electric- or hyaluronidase-mediated 
activation mimics fertilization and promotes cell division towards the formation of 
parthenogenetic blastocysts containing a mixture of haploid and diploid cells22,23.  
Further elaboration on the methods of oocyte activation in mouse showed that this can 
be achieved in many ways, from spontaneous activation upon mechanical handling, 
to thermal, electric or chemical activation24.  Ultimately investigators showed strontium 
chloride (SrCl2) to be the only known parthenogenetic activating agent that induces 
repetitive intracellular calcium releases25-27 in a fashion similar to those following 
normal fertilization by spermatozoa28.  
 
Moreover, it was observed that parthenogenesis may occur spontaneously in mice29 
and women30, leading to the generation of benign ovarian teratomas composed of a 
mixture of diploid and haploid cells, thus highlighting how haploid cells can persist after 
parthenogenesis.  Collectively, these observations led to the development of methods 
for oocyte activation, growth and expansion of parthenogenetic blastocysts and 
subsequent isolation and maintenance of haploid mammalian ESCs from the 
mouse10,11,31-33, the monkey34, the rat35 and human12,13.  Analogously, by transferring 
sperm into an enucleated oocyte, haploid androgenetic ESCs have also been 
derived36,37.  Parthenogenetic haploid ESCs are fully competent for functional 
contribution to the germline38.  
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The generation of mouse and human hESC has opened the door to functional random 
mutagenesis screens39 that have shown that these cells can be successfully used, for 
example, for the identification of loss-of-function and separation-of-function mutants 
via approaches such as ethyl methanesulfonate (EMS) mutagenesis40,41, CRISPR 
screens33,42,43 or transposon induced mutagenesis42.  The use of haploid cells in point 
mutagenesis screens open an important avenue for identification of separation of 
function mutants40.  Using hESC in CRISPR screens allows for higher efficiency as 
one confounding factor in such genome wide approaches in diploid cells is the 
presence of heterozygous deletions.  Moreover, the hESCs are amenable to 
differentiation in different cell types that in the future will allow for screening in a 
multitude of cell lineages43.  Furthermore, the generation of such cells allowed for the 
creation of a cell-bank (Haplobank: www.haplobank.at) of over 100,000 publicly 
available individual mouse hESC lines carrying conditional and reversible disruption 
events in 16,970 mouse genes42. 
 
Limitations of the protocol 
Mouse strain background can play a defining role in the success of haploid ESC 
derivation.  We have derived hESCs from C57BL/6J, NOD/ShiLtJ and 129S1/SvImJ 
genetic backgrounds, and have observed that the success rate was higher for 
C57BL/6J, NOD/ShiLtJ than for 129S1/SvImJ.  Another important limitation of the 
method is the fact that mouse and human hESC spontaneously diploidize upon serial 
passage.  Thus, in order to maintain them a haploid format, cells need to be 
periodically flow sorted from time to time (see Boxes 1 - 3).  Notably, as shown by 
others, we have also observed that the success of hESC derivation can be influenced 
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by the knockout background, for example Tp53 knockout hESC are more stable in 
culture as WT cells.  Another important note is that, with adaptation, hESC become 
more stable and it takes a longer time for them to diploidize (around three weeks 
depending on background and number of cells sorted).  Upon diploidization, ESCs 
remain stable and no longer duplicate their genome (i.e. they do not readily become 
polyploid).  From all the clones that we have karyotyped, we observed low rates of 
chromosomal abnormalities involving mouse chromosome 8, mouse chromosome 11 
and loss of chromosome X, consistent with observations in ESC derived from fertilized 
embryos44,45.  Additionally, the experimenter needs to keep in mind that the 
parthenogenetic hESC derived from oocytes will always contain an X chromosome 
and never a Y chromosome. 
 
Experimental design considerations 
A workflow of the procedure is outlined in Figure 1.  Female mice should be matched 
by genetic background, and ideally the experimenter should start with no less than five 
individual mice.  The use of mice should be compliant with local animal research 
regulations as well as the ARRIVE guidelines46.  If the derivation is done from specific 
knockout lines, in order to obtain both wild type (WT) control and mutants in the same 
derivation, heterozygous mice should be used.  Although an elaborate technique, by 







• Female mice, ideally between 3 to 6 weeks of age.  CAUTION All procedures 
on mice must be carried out following National and Institutional guidelines.  In 
the UK Home Office regulations must be followed with appropriate 
establishment, project and personal licensing in place.  Experiments using 
mouse models should be done in accordance with the ARRIVE guidelines 46. 
• Strontium chloride hexahydrate (Cl2Sr·6H2O; ThermoFisher UK Ltd, cat. no. 
10349220). CAUTION  Harmful if swallowed; irritant.  Consult Safety and 
Hazard sheets that are provided by the seller. 
• Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid tetrasodium 
salt (C14H20N2O10Na4; Sigma-Aldrich, cat. no. E8145). 
• KSOM Mouse Embryo Culture Medium w/ Phenol Red (GlobalStem, cat. no. 
GSM 5140). 
• M2 medium with HEPES, without penicillin and streptomycin, liquid, sterile-
filtered (Sigma-Aldrich, cat. no. M7167). 
• Pregnant mare's serum gonadotropin (PMSG; Prospec Protein Specialists, cat. 
no. HOR 272). 
• Hyaluronidase from bovine testes Type I-S, lyophilized powder, 400-1000 
units/mg solid (Sigma-Aldrich, cat. no. H3506-100MG). 
• Mettler Buffer Sachets pH4 01 Pk30 (Sigma-Aldrich, cat. no. PHM0144). 
• Mettler Buffer Sachets pH7 Pk30 (Sigma-Aldrich, cat. no. PHM0142). 
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• Dulbecco's Phosphate-Buffered Saline (DPBS; ThermoFisher, cat. no. 
14190094). 
• Acidic Tyrodes Solution (Millipore, cat. no. MR-004-D). 
• Hydrochloric Acid Solution, 1.0 N, Bioreagent, suitable for cell culture (Sigma-
Aldrich, cat. no. H9892). CAUTION  Corrosive.  Harmful if swallowed; irritant.  
Consult Safety and Hazard sheets that are provided by the seller. 
• NDiff N2B27 (StemCells Inc., NDiff N2B27; cat. no. SCS-SF-NB-02). 
• GSK3 inhibitor: CHIR99021 (Abcam; cat. no. ab120890).  CAUTION  Acutely 
toxic if swallowed; irritant.  Consult Safety and Hazard sheets that are provided 
by the seller. 
• MEK 1 and 2 inhibitor: PD0325901 (Abcam; cat. no. ab120639).  CAUTION  
Acutely toxic if swallowed.  Consult Safety and Hazard sheets that are provided 
by the seller. 
• ESGRO® Recombinant Mouse mLIF Medium Supplement (LIF) (EMD 
Millipore-Merk; cat. no. ESC1107). 
• Dulbecco's Modified Eagle's medium (DMEM) high glucose with 
UltraGlutamine (Lonza; cat. no. BE12-604F/U1). 
• Gelatin solution (Sigma-Aldrich; cat. no. G1393). 
• Phosphate Buffer Saline (1 x PBS) (Lonza; cat. no. BE17-516F). 
• 2-Mercaptoethanol (Sigma-Aldrich; cat. no. M6250).  CAUTION  Classified as 
an acute toxin; health hazard; environmental hazard; chemical and DNA-
mutagen.  Consult Safety and Hazard sheets that are provided by the seller; 
use only under the chemical cabinet.  Always use hood to prepare solution. 
• Dimethyl sulfoxide (DMSO) (Sigma-Aldrich; cat. no. D2650). 
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• Fetal Bovine Serum (FBS) (Gibco by Thermo Fischer Scientific; cat. no. 
A31608-02). 
• Bovine Albumin Fraction V (7.5% solution) (Gibco by Thermo Fischer Scientific; 
cat. no. 15260037). 
• MEM Non-Essential Amino Acids Solution (100X) (NEAA) (Gibco by Thermo 
Fischer Scientific; cat. no. 11140-050).  CAUTION  Irritant if swallowed.  Consult 
Safety and Hazard sheets that are provided by the seller. 
• Penicillin-Streptomycin-Glutamine (100X) (Gibco by Thermo Fischer Scientific; 
cat. no. 10378-016).  CAUTION  Health hazard if swallowed. Should be 
disposed by appropriate routes.  Consult Safety and Hazard sheets that are 
provided by the seller.  
• Penicillin-Streptomycin (10,000 U/ml) (Gibco by Thermo Fischer Scientific; cat. 
no. 15140122).  CAUTION  Health hazard if swallowed. Should be disposed by 
appropriate routes.  Consult Safety and Hazard sheets that are provided by the 
seller. 
• Sodium Pyruvate (100 mM) (Gibco by Thermo Fischer Scientific; cat. no. 
11360-039). 
• Trypsin-EDTA (0.05%), phenol red (Gibco by Thermo Fischer Scientific; cat. 
no. 25300-054). 
• Trypan Blue Solution, 0.4% (w/v) in PBS, pH 7.5 ± 0.5 (Corning cat. no. 25-
900-CI).  CAUTION Acutely toxic if swallowed; health hazard.  Consult Safety 





• Humidified bench top incubator and stereomicroscope suitable for viewing and 
manipulating embryos using a mouth pipette. 
• Stereo-microscope (Leica cat. no. M125). 
• CO2 incubator (Eppendorf/New Brunswick Galaxy 48R incubator, cat. no. 
CO48R230 or Panasonic cat. no. KM-CC17RU2). 
• Tissue Culture Biological Safety Cabinet (NuAire LabGard ES cat. no. NU-437). 
• pH meter (Mettler Toledo Five Easy FE20, cat. no. 10385343). 
• Fine forceps (Student Dumont #5 forceps, Interfocus Ltd, cat. no. 91150-20). 
• Fine scissors - straight/large loop (Interfocus Ltd, cat. no. 14040-10). 
• Pasteur Pipets (Scientific Laboratory Supplies Ltd, cat. no. PIP4172). 
• Tissue culture grade flasks or plates (Corning cat. no. 430641U or Corning cat. 
no. 430167) 
•  60mm center well culture dish for in vitro fertilization (Falcon 60mm Center well 
culture dish; Scientific Laboratory Supplies Ltd, cat. no. 353653 or similar). 
• Aspirator tube assemblies for calibrated micro-capillary pipettes (Sigma-
Aldrich, cat. no. A5177-5EA). 
 
REAGENT SETUP 
• Strontium chloride. Prepare 100mM SrCl2 using an analytical balance with 
precision of 0.1mg to weigh 26mg and add to 1 ml of KSOM. Make up fresh 
and use within 24hrs. Store at 4C.  CAUTION  Strontium chloride may cause 
serious eye damage or respiratory irritation.  
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• Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA).  Prepare 0.5 M EGTA using an analytical balance with precision of 
0.1mg to weigh 234mg and add to 1 ml of KSOM.  pH adjustment of the EGTA 
solution is important, pH will initially be ~10. Add 1M HCL to the 1 ml EGTA 
solution in increments of 200µl, adding a total of 600µl using the pH meter to 
ensure pH reading = 8.  Make up fresh and use within 24hrs.  Store at 4C. 
• Oocyte Activation Media.   Add 150µl of 100mM SrCl2 and 12µl of 0.5M EGTA 
to 3 ml of KSOM and filter sterilise.  Store at 4˚C for use the following day or 
put 2 ml in 60 mm centre well culture dish, surrounded by PBS in outer well, 
and pre-equilibrate to 37 ˚C for use on the same day.  
• Hyaluronidase.  Make a stock solution of hyaluronidase by adding 3.53 ml of 
M2 to 100 mg lyophilised powder.  Gently agitate the solution ensuring powder 
is fully dissolved.  Make working concentrations by adding 100 µl of 30 mg/ml 
stock hyaluronidase solution to 900 µl M2 to create a 3mg/ml solution.  Sterile 
filter and aliquot into 200 µl aliquots and store at -20 ˚C for up to 1 year.  For 
use in removal of oocyte cumulus cells, add 1 aliquot of 200 µl solution to 1.8 
ml M2. 
• Pregnant mare's serum gonadotropin (PMSG).  Prepare PMSG in a clean 
class 2 safety cabinet.  Reconstitute the 5000 international units (IU) lyophilised 
powder by mixing with 80ml PBS ensuring powder is completely dissolved.  
Aliquot into 1.5 ml vials and store at -20 ˚C to use for up to 3 months.  
• Human chorionic gonadotropin (HCG).  Prepare HCG in a clean class 2 
safety cabinet. Reconstitute the 1500 IU lyophilised powder by mixing with 30ml 
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PBS ensuring powder is completely dissolved.  Aliquot into 1.5 ml vials and 
store at -20 ˚C to use for up to 3 months. 
• NDiff-N2B27 culture media.  To 94 ml NDiff N2B27 media add: 5 ml 7.5% 
BSA, 1 ml Penicillin-Streptomycin (100X), 10 µl LIF, 1µl 2-Mercaptoethanol and 
2i (10 µl PD (10 mM stock; stored at 4˚C) and 30 µl CHIR (10 mM stock; stored 
at -20˚C)).  NDiff-N2B27 culture media can be stored at 4˚C for up to one month. 
 CAUTION  2-Mercaptoethanol is classified as a severely toxic chemical and 
DNA-mutagen.  Consult Safety and Hazard sheets that are provided by the 
seller, use only under the chemical cabinet. 
• DMEM culture media.  To 500 ml DMEM high glucose media (1 bottle) add: 
75 ml FBS, 6 ml NEAA (100X), 6 ml Sodium Pyruvate (100 mM), 6 ml Penicillin-
Streptomycin-Glutamine (100X), 60 µl LIF, 6 µl 2-Mercaptoethanol.  Optional: 
if 2i addition is required (see Method) add 60 µl PD (10 mM stock; stored at 
4˚C) and 180 µl CHIR (10 mM stock; stored at -20˚C).  DMEM culture media 
can be stored at 4˚C for up to one month. 
CAUTION  2-Mercaptoethanol is classified as a severely toxic chemical and 
DNA-mutagen.  Consult Safety and Hazard sheets that are provided by the 
seller; use only under the chemical cabinet. 
• 0.02% Gelatin solution.  Allow 2% gelatin solution to completely liquefy at 
37°C and make 0.02% gelatin working solution with 1 x PBS (e.g. 5 ml 2% 






• Stereo microscope with heated stage.  Manipulating embryos is done using 
a stereomicroscope with heated stage and zoom capacity up to 100x 
magnification. 
• Humidified incubator.  Oocytes in activation medium and all subsequent 




Timing: 30-40 minutes  
1 | Identify female mice to use as donors for oocyte production to be superovulated 
between the ages of 3-4 weeks and set aside in advance.  CAUTION  All 
procedures on mice must be carried out following appropriate National regulations.  
In the UK this means in accordance with Home Office regulations and with 
appropriate establishment, project and personal licensing in place.  CRITICAL 
STEP Note that the best age for superovulation varies from strain to strain but 
usually lies between 3 and 6 weeks of age, during the prepubescent stage of 
development47. 
2 | Inject the mice at 3pm, removing the PMSG hormone (6.25 IU, 0.1ml for each 
female mouse) from the freezer 15-20 minutes before the injections are scheduled 
to allow the hormone to defrost and warm to room temperature. 
3 | Once completely defrosted draw up the hormone into a 1 ml syringe making sure 
there are no air bubbles in the syringe.  Attach a 27 G needle to the syringe, hold 
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with the needle facing up and depress the syringe plunger to expel air from the 
dead space created. 
4 | Scruff the mouse and turn it so its stomach is facing upwards and its head is slightly 
tilted back.  
5 | With your free hand, hold the syringe so the needle is bevel side up.  Carefully 
insert the needle into the peritoneal cavity of the mouse, to the left or right of the 
midline of the mouse making sure not to hit the bladder.  
6 | Following your approved technique for mouse intra peritoneal (IP) injection, 
administer 6.25 IU PMSG, 0.1 ml.  Briefly, after preparing the PMSG solution draw 
it up in the syringe, with keeping in mind dead volumes in the needle.  Gently 
remove the animal from the cage and restrain appropriately in the head‐down 
position.  Disinfect lower right quadrant of the abdomen with 70% ethanol and inject 
by inserting the needle with bevel facing up at approximatively 30ᵒ angle to 
horizontal towards the head in order to avoid damage to the urinary bladder, cecum 
and other abdominal organs.  Wait briefly before withdrawing the needle to make 
sure the liquid does not seep out.   
 
7 | Place the mouse into an empty cage and then repeat steps 5 – 6 for each mouse 
until finished.  Once all mice have been injected they can then be returned to their 
original cage. 
8 | Dispose of the needle and syringe in a sharps bin.  CAUTION  Extreme caution is 
required at all times when handling used sharps.  Dispose sharps directly without 
capping. 
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9 | Repeat steps 2-8 46-48 hours after PMSG administration. but inject with 0.1 ml, 5 
IU HCG rather than PMSG. 
 
Dissection and oocyte harvest  
Timing: 50 – 60 minutes  
10 | Set up 4 single well dishes per line; 1 containing activation medium and 3 with 
KSOM for washing.  There should be 1 ml of culture media in the centre well with 
2-3 ml of DPBS in the outer well. 
11 | Filter 10 ml of M2 into a Falcon tube using a Millex - GS 0.22 µm filter and place 
in an incubator to warm to 37˚C. 
12 | Remove 1 vial of hyaluronidase (working stock solution) from the -80 freezer 
and thaw in an incubator, warming to 37˚C. 
13 | Place a 50mm dish containing 2-3 ml of M2 or 0.9% saline on a heat blanket or 
warming stage set to 37˚C. 
14 | Cull a female by cervical dislocation, lay the mouse on its back exposing the 
abdomen. 
15 | Make a midline incision up and though the abdominal wall followed by the 
peritoneal sac to expose the internal organs, pushing the gut up and out toward 
the chest revealing the reproductive organs. 
16 | Grasp the upper end of one of the uterine horns with fine forceps and gently 
pull the uterus, oviduct, ovary, and fat pad taut and away from the body cavity.  
This will reveal a fine membrane, the mesometrium, which connects the 
reproductive tract to the body wall and carries a prominent blood vessel.  Make a 
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hole in the membrane close to the oviduct with the closed tips of a pair of fine 
forceps or scissors. 
17 | Reposition the forceps and cut the uterus near the oviduct. 
18 | Transfer the oviduct and attached segment of uterus to the 50 mm dish 
containing DPBS at 37 ˚C.  
CRITICAL  It is important to keep oocytes at 37˚C at all stages to maintain oocyte 
viability and chances of successful parthenogenesis.  
19 | Repeat steps 14-18 for all females; oviducts from several mice can be collected 
in the same dish.  
20 | Prepare a 35 mm dish containing 2 ml of filtered M2 for washing oocytes after 
exposure to hyaluronidase.  Keep the dish at 37˚C. 
21 | Pipette 1.8 ml of the pre-warmed M2 into a 35 mm culture dish. 
22 | Move 1 x oviduct into the dish with the 1.8 ml filtered M2 and ‘pop’ the swollen 
ampulla to release the cumulus mass, then discard the oviduct.  Repeat until all 
oviducts have been processed. (Supplementary Video 1). 
23 | Add all the hyaluronidase working stock solution from the vial and gently 
swirl/agitate the dish to help dispersal of cumulus mass or pipette up and down 
gently several times with a 1 ml tip, then wait for the cumulus cells to start falling 
away leaving individual oocytes.  
CRITICAL  Hyaluronidase can have a detrimental effect on the oocyte, so the 
oocytes should be collected and washed quickly.  Reducing the amount of 
hyaluronidase added to the M2 will increase the time it takes embryos to become 
free from cumulus cells but will allow more time for users less familiar with the 
protocol to collect the oocytes. 
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24 | Pick up the individual oocytes with a transfer pipette and place into the 2 ml of 
warmed M2, repeating until all oocytes are collected.  
Troubleshooting 
25 | Wash oocytes through 6 x drops of pre-warmed, filtered M2.  Once washed the 




Timing: 2-3 hours  
26 | Remove oocytes which have lysed, fragmented or have a large perivitelline 
space (shrunken cell).  A lysed cell of an oocyte will look darker in comparison to 
a healthy oocyte.  Fragmentation of a single cell can occur and can vary from a 
section to the entire cell.  A larger perivitelline space can be obvious when the 
oocyte is placed next to healthy examples.  Sometimes the increased perivitelline 
space is all around the circumference of the cell, other times it is more obvious on 
one side of the oocyte.  If in doubt, the oocytes can be retained and put in activation 
medium to be removed later if necessary.  Aspirate the oocytes around a drop of 
M2 with a mouth pipette, rolling the oocytes to allow viewing from a variety of 
angles under a bench top stereomicroscope to make the assessment thorough. 
27 | Move any oocytes identified as sub-viable to a separate drop of M2 for final 
assessment.  Discard sub-viable oocytes (Supplementary Video 2). 
28 | Transfer all viable oocytes to the pre-incubated activation medium and place in 
tissue culture for 90 minutes at 5% CO2, 37˚C. 
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CRITICAL  Viable oocytes must be placed in to the activation medium for the stated 
time and without delay to optimise chances of successful parthenogenic activation.  
29 | Remove oocytes from activation medium by gently mouth pipetting and wash 
through 3 dishes of pre-equilibrated KSOM.  
30 | Observe the oocytes for polar body extrusion, indicating successful activation.  
Once the oocytes are in the activation media it takes up to 90 minutes for all the 
oocytes to be activated (polar body extrusion).  
31 | Culture oocytes for 72 hours. 
 
Selection of blastocysts  
Timing: 50 – 60 minutes  
CRITICAL  This part is outlined in Figure 2. 
32 | On day 3 post activation, embryos will be at a variety of developmental stages: 
some embryos will look sub viable and some may have lysed (Figure 2a).  Remove 
lysed embryos but retain those where cells have not divided cleanly as they may 
still progress to blastocyst. 
Troubleshooting  
33 | Move 8-cell embryos to KSOM supplemented with CHIR99021 (3 µM) and 
PD0325901 (1 µM), pre-equilibrated to 5% CO2, 37˚C and continue to culture. 
34 | On day 4, there will be some embryos that have developed to blastocyst that 
are suitable for zona pellucida removal (Figure 2b).  Only select embryos that have 
a well expanded blastocoel for zona removal. 
35 | Repeat steps 32 to 34(the check and selection of blastocysts for zona removal) 




Zona pellucida removal  
Timing: 30 minutes  
CRITICAL  When handling embryos, process one line at a time to make sure that 
strains do not get mixed and label all dishes and vials containing embryos with strain 
information or a unique identifier. 
 
36 | Pre-warm acidic Tyrodes solution to 37˚C. 
37 | Put two ~200 µl drops of acidic Tyrodes and two ~200 µl drops of M2 on to a 
dish suitable for working under a stereo microscope.  
38 | Select the blastocysts for zona removal and move to one of the M2 drops.  
39 | Transfer the blastocysts to the first drop of acidic Tyrodes and observe the 
dissolving of the zona.  The zona should take 30-70 seconds to dissolve. 
Troubleshooting 
40 | Briefly aspirate the blastocysts up and down the mouth-pipette to ensure the 
zona is completely removed and transfer to the second drop of M2 (Supplementary 
Video 3 and Supplementary Video 4).  
41 | Observe the blastocysts in M2 and manipulate using a new mouth-pipette to 
check that the zona has been completely removed (Figure 2d; Supplementary 
Video 4).  If the zona remains intact after inspection, repeat steps 38 to 41 using 
a second drop of acid. 
Troubleshooting 
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42 | When the zona’s have been removed, immediately transfer the blastocysts to 
a fresh dish of M2. 
Troubleshooting 
43 | Wash blastocysts through an additional 2 dishes of M2. 
44 | If transporting blastocysts, pipette 50 µl of M2 into a 1.5 ml microcentrifuge tube 
and label with strain and embryo number.  Using a mouth pipette and M2, load an 
air bubble to be positioned behind the blastocyst and transfer embryos to the vial.  
The bubble behind the blastocysts should come from the pipette indicating 





ESC cell line establishment 
Timing: 10 - 20 days 
45 | Coat plates with 0.02% gelatin for 5 minutes (100 µl/well).  It is not necessary 
to wash the plates after removal of gelatin solution. 
46 | Transfer denuded embryos to individual wells of 96-well plates containing 250µl 
NDiff-N2B27 culture media (see Reagents set-up). 
47 | Culture embryos until they grow into visible cellular colonies (around 1 mm in 
size; this takes up to 10 days in culture) (Figure 2e). 
CRITICAL  Pay particular attention to retaining the colony if media change is 
required (if media starts to become yellow in colour), as the colony will not attach 
strongly to the bottom of the dish. 
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48 | Transfer a unique colony to 15 µl trypsin and, after 2-3 minutes, pipette up and 
down using 15 µl DMEM culture media to inactivate the trypsin and transfer to 
another well of a 96-well gelatin coated plate containing 250 µl NDiff-N2B27 culture 
media. 
CAUTION  Haploid ESC diploidize faster in DMEM culture media than in NDiff-
N2B27 culture media.  Do not try to spin down the cells after trypsinization, as it is 
very easy to lose the lines when doing this. 
49 | In 3 days or upon confluency, trypsinise as described in step 48 and re-plate in 
a gelatin coated 24 well plate; at this point the hESC will form colonies (Figure 2e). 
50 | In 3 days or upon confluency, trypsinise as described in step 48 (increasing the 
trypsin volume accordingly to cover the bottom of the well; e.g. 50 µl trypsin) and 
block trypsinization with an equal volume of DMEM culture media.  Transfer cells 
to a gelatin coated 6 well plate; at this point flow cytometry cell cycle analysis can 




51 | In 3 days or upon confluency, trypsinise cells as described in step 48 and 
transfer them to a gelatin coated 10 cm dish or T25 flask.  The first sorting for 
haploid enrichment can also be performed (see Box 3).  Plate sorted cells in a 
gelatin coated T25.  Troubleshooting 
52 | Upon regrowth, trypsinise (Step 48) and split into several gelatin coated flasks 
or 10cm dishes, 1 million/flask and in 2 days freeze down some cells in 1 ml 1:9 
DMSO : FBS freezing media and transfer to a liquid nitrogen storing unit.  From 
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this point onwards, one of the clones can be adapted to DMEM with 2i and LIF.  If 
desired, cells can be adapted in DMEM with LIF alone.  
 
TIMING 
It is recommended that the superovulation dates are on Tuesday and Thursday, as 
this allows mouse dissection, oocyte harvest and activation on a Friday followed by 
embryo culture over the weekend and assessing for blastocysts during the weekdays 
of the following week.  
 
Day 1 (Steps 1 to 8): Inject female donors: 0.1 ml, 6.25 IU PMSG, 3 pm 
Day 3 (Step 9): Inject female donors: 0.1 ml, 5 IU HCG, 3 pm 
Day 4 (Steps 10 to 31): Dissection of female donors, harvesting and activation of 
oocytes. 
Day 7 (Steps 32 and 33): Remove lysed embryos and transfer 8 cell embryos to KSOM 
supplemented with 2i. 
Day 8 (Step 34 and 35): Some embryos will have developed to blastocyst; select those 
with the largest blastocoel for zona removal. 
Day 9 (Step 36 to 44): Most blastocysts should be available for zona removal on this 
day.  Move the remaining embryos into fresh, pre-equilibrated KSOM for further 
culture. 
Day 10 (Repeat steps 37 to 46): Zona removal of the remaining blastocysts. 
Day 11 (Steps 45 to 47): Transfer to tissue culture room in NDiff-N2B27 culture media 
(about 3 minutes/blastocyst on average). 
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Day 18 (Step 48): Passage to 96 wells.  Most blastocysts will expand to cellular 
colonies by this point but some might need additional days (about 15 minutes/cell line 
on average). 
Day 21 (Step 49): Passage to 24 wells (about 15 minutes/cell line on average). 
Day 24 (Step 50): Passage to 6 well plate (about 15 minutes/cell line on average). 
Day 27 (Step 51, 52 and Box 1 and Box 2): Passage to T25 flask or 10 cm dish and 
cell cycle profile, genotyping and mycoplasma testing (about 15 minutes/cell line on 
average). 
Day 30 (Optional. Repeat Steps 51 and 52): Expansion to T75 flasks (about 15 
minutes/cell line on average) to increase the number of sorted cells. 
Day 33 (Box 3): Sorting for haploid enrichment (about 2-3 hours/cell line on average 
- depending on the haploid content). 
Day 36 to 46 (Repeat Steps 50 to 52): Depending on how many cells have been 
sorted, expansion of haploid populations and freeze down for banking of cell lines 
(about 15 minutes/cell line on average). 
 
TROUBLESHOOTING 
See Table 1 for troubleshooting guidance. 
 
ANTICIPATED RESULTS 
The protocols presented here will allow derivation and maintenance of mouse haploid 
ESCs.  Although the protocol for derivation of hESC is lengthy (about seven weeks), 
it allows reliable and reproducible derivation of hESCs.  In our hands mouse hESCs 
can be successfully established in gelatin coated plates, with only minor improvements 
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when deriving them on plates containing irradiated feeders.  The bottleneck for 
successful cell line production is the quality of the embryos selected.  This can vary 
depending on mouse strain, mouse age, handling of oocytes, decision on what 
oocytes to select, successful activation, subsequent decision on what blastocysts to 
select and successful zona pellucida removal.  In our hands, from 1534 oocytes, we 
had overall success rates of 1 blastocyst for each 10.5 oocytes (1 blastocyst for every 
3.95 oocytes if we do not include oocytes that do not progress within 24 hours and 
that were unlikely to be viable in the first place).  Our activation success rate is 1 per 
2.65 oocytes and our average success rates for cell line production is 1 cell line for 
every 1.4 blastocysts used.  Although there might be a minor advantage to using 
feeders, for users that do not have much experience with handling ESCs on feeders, 
culture without feeders is the most straightforward to undertake as it allows easier 
identification of the haploid ESCs colonies.  We recommend that before freezing down 
the cellular clones a mycoplasma test be performed.  In our hands we have never had 
any mycoplasma contamination.   
The associated procedures allow for the screening of clones that contain haploid 
populations (see Box 1), karyotyping of the isolated hESC clones (see Box 2) and 
sorting for enrichment of hESCs (see Box 3).  We also describe considerations for 
use of hESCs imported from the Haplobank (see Box 4).  Haploid cells can be 
subsequently successfully used for genetic screens (see Box 5 for one such example).  
Similar principles can be used for the maintenance and propagation of human haploid 
ESCs.  
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Box 1 Quantification of cell cycle profile of newly derived ESC 
Reagents 
• Propidium iodide (PI) solution (Sigma-Aldrich; cat. no. P4864).  CAUTION  
Health hazard if swallowed; mutagen.  Consult Safety and Hazard sheets that 
are provided by the seller. 
• SpheroTM Rainbow Fluorescent particles, Spherotech (cat. no. RCP-20-5). 
Equipment 
• BD Falcon™ Round-Bottom Tubes (BD, Polypropylene, 5 ml, snap, cat. no. 
352063). 
• 30 µm filters (Sysmex, CellTrics 30 µm green; cat. no. 25004-0042-2316)  




• FACS buffer.  0.5% BSA in 1 x PBS. Can be stored for up to 1 month at 4 ºC. 
• PI solution.  10 µg/ml PI, 250 µg/ml RNase in FACS buffer.  Make fresh. 
 
Sample preparation 
Timing: 1 hour   
 
1 | (Optional) Collect media from the plate/well into a 15 ml conical tube and place it 
on ice. 
2 | (Optional) Wash the plate/well with 2 ml of 1 x PBS and collect them in the same 
tube.  
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CRITICAL  Steps 1 and 2 are important if floating cells (i.e. dead or mitotic) are to 
be taken in account, otherwise the experimenter can just remove medium, wash 
with 1 x PBS and proceed to step 3. 
3 | Add 1 ml trypsin (for a 6 cm dish) and incubate for a few minutes at 37 °C. 
4 | Harvest trypsinized cells into the tube from step 2, if available. 
5 | Filter cells through a 30 µm filter to remove any cell clumps and count cells. 
CRITICAL  Proceed with 1 million cells up to 5 million cells depending on how 
many cells are available.  For consistency of comparison with diploid control 
across the gates, it is important to keep all the samples at the same cell 
concentration (so that voltage settings on the flow cytometer do not need to be 
changed). 
6 | Centrifuge 5 min at 450 g and discard supernatant. 
7 | Resuspend cells in 5 ml of ice-cold 1xPBS containing 1 mg/ml BSA. 
8 | Centrifuge 5 min at 450 g, discard the supernatant and resuspend cells in the 
residual liquid. 
9 | Add 4 ml of ice-cold 70% ethanol drop wise using the vortex. 
10 | Incubate samples at -20 °C for at least 30 min.  
Pause point: Cells can be kept at -20 °C for weeks. 
11 | Centrifuge 5 min at 450 g and discard supernatant. 
12 | Resuspend cells in 0.5 ml PI reagent and transfer cells to a FACS tube.  





Flow cytometric analysis 
Timing: 30 minutes for 10 samples 
13 | Using the diploid control, acquire events with SSC-A-Lin versus FSC-A-Lin axes. 
The SSC-A-Lin versus FSC-A-Lin plot should reveal one population.  Centre the 
main population using the voltage and gain settings and create the first gate (R1: 
ESCs) (Figure 3a).  
14 | Isolate doublets by plotting FSC-W-Lin versus FSC-A-Lin and set gate R2 around 
single cells (Figure 3b). 
CRITICAL  In the case of the haploid/diploid cells the doublet cell population will 
reveal two overlapping populations, haploid (n; below) and diploid (2n; above); 
when the first experimental sample is run doublecheck that the haploid 
population is not excluded). 
15 | Isolate the live cells by plotting FSC-W-Lin versus PI stain to identify dead cells 
(left side) and events caused by auto-fluorescence (right side) and remove them 
by setting gate R3 on the PI population (Figure 3c). 
CRITICAL  In the case of the haploid/diploid cells the doublet cell population will 
reveal two populations overlapping at the 100 K mark: haploid (n; at 50 K to 100 
K) and diploid (2n; 100 K to 225 K); when the first experimental sample is run 
doublecheck that the haploid population is not excluded. 
16 | On Count-Lin versus PI-Lin axes resolve the cell cycle profile.  Acquire at least 
10,000 events.  On a cell line that contains a mix of haploid/diploid cells there will 
be evident (Figure 3d):  
• Haploid G1 phase of the cell cycle (hG1) at the 50K mark; 
• Haploid S phase of the cell cycle (hS1) between 50K to 100K marks; 
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• Overlapping haploid G2 phase of the cell cycle (hG2) and diploid G1 phase 
of the cell cycle (dG1) populations at the 100K mark; 
• Diploid S phase of the cell cycle (dS) between 100K and 200K mark; 
• Diploid G2 phase of the cell cycle (dG2) at the 200K mark. 
Figure 4a shows a depiction of the cell cycle profiles of 3 random WT clones. 
CRITICAL  It is critical to run first the diploid only control to recognize the diploid 
cell cycle peaks.  Some experimental samples might be pure haploid populations 
and without a diploid control it will be impossible to tell them apart.  
17 | Save the experiment settings and experimental analysis on the flow cytometer. 
  
 32 
Box 2 Chromosomal analysis of hESC 
Reagents 
• KaryoMAX® Colcemid™ Solution in HBSS (ThermoFisher cat. no. 15210040; 
10 μg/ml (stock)).  CAUTION  Acutely toxic if swallowed; health hazard.  
Consult Safety and Hazard sheets that are provided by the seller. 
• KCl (Sigma-Aldrich; cat. no. P9333). 
• Acetic acid (>99.7%) (Sigma-Aldrich; cat. no. 695092-500ML-D).  CAUTION  
Acutely toxic if swallowed; flammable; corrosive.  Consult Safety and Hazard 
sheets that are provided by the seller. 
• Methanol (>99.8%) (Sigma-Aldrich; cat. no. 179337-2.5L-D) (methanol: acetic 
acid; 3: 1).  CAUTION Acutely toxic if swallowed; flammable.  Consult Safety 
and Hazard sheets that are provided by the seller. 
• Antifade Mounting Medium with DAPI (Vectashield laboratories; cat. no. H-
1200).  CAUTION  Health hazard if swallowed; mutagen.  Consult Safety and 
Hazard sheets that are provided by the seller. 
 
Equipment 
• Glass histology slides (75x25) (ThermoFisher; cat. no. 4951PLUS4). 
• Glass coverslips (60x24) (ThermoFisher; cat. no. Q10143263NR). 







• Hypotonic solution.  5.6 g KCl in 100 ml H2O (0.75M, stock); 10X dilution of 
stock (working solution).  Working solution should be made fresh; stock can 
be stored at room temperature for one year. 
• Methanol:acetic acid fixative. Mix 3:1 methanol:acetic acid (i.e. mix 30 ml 
methanol with 10 ml acetic acid).  Always make on the day.  CAUTION.  Work 
under the chemical hood to prepare the fixative.  Acutely toxic if swallowed; 
flammable.   
 
Sample preparation 
Timing: 1 day and 3 hours 
1 | One day prior to karyotyping prepare a gelatinised plate by adding 5 ml 0.02% 
gelatin and leaving for 5 minutes prior to plating. Then passage 1 million hESC 
onto a 10 cm gelatinised plate.  
2 | Add microscope slides to a jar containing 70% ethanol (this will degrease the 
slides and allow optimal adherence).  
3 | 24 hours later add 200 µl Colcemid to the culture to achieve a final 
concentration of 0.2 μg/ml. Return the flask to the incubator and continue 
incubating for 45 minutes. 
4 | Prepare working hypothonic solution (10X stock) 4 ml for each sample and 
place it in a 37 °C water bath. 
CRITICAL The hypotonic solution needs to be 37 °C for optimal hypotonization.  
5 | Prepare the Methanol : Glacial Acetic Acid (3 : 1) fixative solution and place on 
ice. 
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6 | Wash the plate vigorously 2-3 times with the media covering the cells and save 
it in a 15 ml conical tube; 
CRITICAL  Most metaphases will be loosely attached to the plate and will be 
harvested at this step. 
7 | Wash the plate gently with 1 x PBS and trypsinise the hESCs using 1.5 ml 
trypsin for 1 - 2 minutes in the incubator. 
8 | Wash the cells with the media from the 15 ml conical tube (step 6) and harvest 
them in the same conical tube; this media will also stop trypsin action.  
9 | Centrifuge the cells at 450 g for 5 minutes and discard the supernatant by 
inverting the conical tube. 
10 | Add 6 ml working hypotonic solution and mix well by pipetting up and down. 
11 | Incubate cells for 6 minutes at 37 °C. 
CRITICAL  Optimal hypotonisation is highly dependent on this incubation 
step. Under-hypotonisation will not break the cell wall.  Over-hypotonisation 
will lead to chromosomes dissociating from the metaphase plate.  If doing 
more than 4 samples, stagger them at this step so only 4 samples are 
processed at a time. 
12 | Stop hypotonization by adding 1 ml cold fixative to each sample and mix by 
gentle inversion 2 - 3 times. 
13 | Centrifuge the cells at 450 g for 5 minutes and discard the supernatant by 
inverting the conical tube. 
14 | Resuspend the cell pellet in the residual liquid by flicking the tube.  
CRITICAL  It is important to resuspend the cells well at this step otherwise 
clumps will form and it will be hard to resolve single metaphase spreads. 
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15 | Using a Pasteur pipette, carefully add 2 ml of fixative solution dropwise, with 
gentle mixing to avoid clumping.  Add an additional 6 ml of fixative and mix by 
gentle inversion of the tube. 
CRITICAL  It is important to gently add the fixative at the first fixation as this 
will have a big impact on the metaphases (chromosomes can dissociate from 
the metaphase plate).  The fixative needs to be freshly made. 
16 |  Incubate the metaphase preparations on ice for 30 minutes. 
17 | Centrifuge cells (450 g, 5 minutes) and discard the supernatant. 
Pause step: At this step the metaphase preparations can be stored at -20 for 
years.  
18 | Repeat steps 13 - 16 three times to clear the cytoplasm. 
19 | Before spotting on slides resuspend the pellet in a small amount (0.5 ml) of 
fixative (this volume may need to be adjusted slightly according to cell 
number). 
20 | Spot 2 - 3 drops in a row on each slide.  Allow slide to dry.  Humidity will affect 
spreading of metaphases (higher humidity will increase spreading). 
If FISH analysis is desired follow the protocol by Rens W. et al. (2006)48. 
21 | Mount slides using antifade mounting medium with DAPI, cover with a 
coverslip and seal.  A representative karyotype of a hESC clone is presented 
in Figure 4b. 
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Box 3 Sorting of haploid ESC 
Before preparing the sort bear in mind you should always have a fully diploid control 
ESC cell line available to stain side by side to be able to calibrate the cell cycle profiles 
on the sorting machine.  Before starting the cell harvest procedure fill to the edge two 
BD Falcon round-bottom tubes with warm ESC DMEM culture media and leave at 
room temperature in the hood for at least 30 minutes (the serum from the media will 
prevent cells sticking to the walls and not being collected in the collection media) and 
gelatinize T75 flasks using 5 ml 0.02% gelation solution for 5 minutes. Prepare a 
bucket of ice to store and transport the cells to and from the sorter. 
Reagents 
• 70% Ethanol (Fisher Bioreagents, Cat. No. BP8201-1).  CAUTION  Flammable.  
Irritant if swallowed.  Consult Safety and Hazard sheets that are provided by 
the seller. 
• Hoechst 33342, Trihydrochloride, Trihydrate - 10 mg/ml Solution in Water 
(Invitrogen; ThermoFischer Scientific cat. no. H3570).  CAUTION  Health 
hazard if swallowed; mutagen.  Consult Safety and Hazard sheets that are 
provided by the seller. 
• Verapamil hydrochloride (Sigma-Aldrich; cat. no. V4629); working solution 100 
μmol/L.  CAUTION  Acutely toxic if swallowed; environmental hazard.  Consult 
Safety and Hazard sheets that are provided by the seller.  






• BD Falcon™ Round-Bottom Tubes (BD, Polypropylene, 5 ml, snap, cat. no. 
352063). 
• 30 µm filters (Sysmex, CellTrics 30 µm green; cat. no. 25004-0042-2316). 
• Flow cytometer (Beckman Coulter; CytoFLEX S Flow Cytometer or similar, 
Model B75442). 
• Cell sorter (BD Biosciences; BD Influx or similar cat. No. 646500).  
 
Reagent setup 
• FACS buffer.  0.5% BSA in 1 x PBS. Can be stored for up to 1 month at 4 ºC. 
• Hoechst working solution. 1 µg/ml Hoechst in DMEM culture media. (e.g. 
add 1 µl of 10mg/ml Hoechst 33342 stock for each 100µl DMEM culture 
media). Make fresh. 
 
Sample preparation 
Timing: 1 hour 
1 | Wash cells with 1 x PBS, trypsinize using 1 ml Trypsin and take up cells in 
DMEM culture media (10 ml for a T75 flask) by pipetting up and down a couple 
of times. 
2 | Filter using 30 µm filters to remove cell clumps in a new 15 ml conical tube. 
3 | Transfer cells to a 15 ml conical tube and spin down at 450 g for 5 minutes; 
discard the supernatant and re-suspend in appropriate volume of NDiff-N2B27 
culture media (0.5 ml minimum for a T25 or 1 ml for a T75 flask). 
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4 | Prepare Hoechst working solution in DMEM culture media (e.g. 3µl in 300 µl 
DMEM culture media). 
CRITICAL  For some applications such as point mutagenesis screens, it is 
advised to avoid the use of Hoechst dye for setting up the gates and instead  
sort by size only. 
5 | For each ml of cell suspension, add 100 µl of 1 µg/ml Hoechst working solution 
to a final Hoechst concentration of 10 µg/ml.  Incubate in the tissue culture 
incubator for up to 30 minutes with gentle resuspension every 10 minutes. 
6 | (Optional) If you so wish, add verapamil (an inhibitor of calcium pumps and 
hence any G1 to S transition) to staining buffer to promote the identification of 
hG1 phase cells. 
7 | Filter into a new flow cytometry tube using 30 µm filters to remove cell clumps.  
Aspirate media from the collection tubes allowing 0.5 ml residual and transport 
the collection tubes, the diploid control tube and the sample tubes to the sorting 
machine for sorting. Sorting can take 2 – 3 hours (depending on how many cells 
are sorted).   
CRITICAL  As with any cell sorting protocol make sure the sorting machine is 
clean before sorting so that contamination with other cells or pathogens is 
avoided. 
8 | Align the optical light path of the flow cytometer before cell analysis using 3 µm 
beads (SpheroTM Rainbow Fluorescent particles, Spherotech) with minimum 
peak coefficient of variance (CV) for all fluorescence channels.   
CRITICAL  In parallel, stain as above the same (isogenic) cell line that has 
been allowed to diploidize previously.  Using small aliquots (e.g. 100 µl) prepare 
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a 1: 1 mixture from the haploid line for sorting and the isogenic diploid line.  This 
step will allow the clear differentiation between haploid/diploid populations.  
9 | Sort the G1 haploid population following the gating strategy depicted in Figure 
5 and collect as many cells as possible.  Haploid cells can be sorted as single 
cells in 96 wells.  The clones selected this way have different haploid latency 
times (see Figure 5d).  If for downstream experimental purposes (e.g. point 
mutagenesis) the use of Hoechst dye is not desired, establish the gates with 
a small subpopulation of Hoechst stained cells, and then sort the bulk of the 
cells by size (mouse haploid ESCs are approximatively half the size of diploid 
isogenic ESCs).  Precaution must be taken not to mistakenly gate out the 
diploids as doublets. 
CRITICAL  Sort the bulk of the hG1 population and avoid the sub-hG1 
population that might contain cells that have lost chromosome X (mESCs are 
reported to randomly loose the X chromosome45). 
10 |  Centrifuge the sorted cells down (450 g) and resuspend in hESC media. 
11 |  Plate cells in appropriate flasks or dish containing hESC media and allow for 
recovery. 
The haploid ESC can be sorted as a bulk population or as single cell clones.  While 
the sorting of a bulk population reliably obtains almost pure haploid populations, 
sorting individual cells has different rates of success due to the long time these 
cells have to be in culture before they can be expanded for banking.  An example 
of the haploid status of 3 individual clones from sorting 3 individual WT cells is 
presented in Figure 5e.  
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Box 4 Haplobank 
 
The Haplobank (www.haplobank.at) contains over 100,000 cell lines covering about 
17,000 genes in the mouse genome and thus represents the largest homozygous ESC 
library available to the scientific community to date42.  These cell lines are on/off 
systems that allow for conditional induction of gene disruption and subsequent 
reversal allowing for fast complementation to be performed for validation.  Moreover, 
these mutants were engineered in single cell derived clones and are thus isogenic, 
therefore allowing for improved reproducibility across different comparisons not only 
in one laboratory but across the scientific community.  Such a resource will permit the 
broad and robust interrogation of the functional genome.  
Below we highlight information to help with the decision making when selecting clones 
from the Haplobank website and the protocol for gene trap flipping.  The constructs 
used for disrupting are presented in Supplementary Figure 1a and their sequences 
are available as Supplementary Data.  
 
Decision points: Selection of clone   
• Sense: disruptive (knockout; WT conditional ready). 
• Antisense: non-disruptive (WT; knockout conditional ready). 
• Clones highlighted in green: homozygous integration sites are confirmed. 
• Clones highlighted in blue: only one gene trap insertion (should be first choice). 
• Clones highlighted in grey: more than one gene trap insertion (should be 
second choice). 
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• 1Intron, Intron, 5'UTR, CDS, and ncExon: disruptive mutations.  If possible, we 
would recommend going for an insertion in the first Intron (1Intron).  Keep in 
mind that a mutation in the coding sequence is phenotypically not reversible. 
• Upstream, InterDown and InterUp carry the gene trap in an intergenic region 
and cannot be regarded as knockouts. 
• The choice of the mutagen is then the last thing: Tol2GT/Retro/Lenti are 
enhanced gene traps while Tol2 is a polyA- enhanced gene trap that carries 
EGFP. 
• The insertion site is predicted with high certainty to be disruptive for all RefSeq 
transcripts of this gene.  The splice acceptor is integrated in a genomic locus 
common to all RefSeq transcripts (intronic and exonic) and before 50% of the 
longest open reading frame. 
• Integration sites were identified using three different approaches: two inverse 
PCRs using the two different restriction enzymes E1 (Supplementary Figure 
1b, Table 2 and Table 3) and a barcode PCR, all followed by next generation 
sequencing.  If the mapping strategy was successful, it has a green light. 
 
Gene trap flipping: Infection of murine ESC  
Timing: 3 - 4 days 
CRITICAL  Gene trap cassettes harbouring disruptive splice acceptor sites are 
integrated either in sense or antisense relative to corresponding gene transcripts.  This 
will lead to disruptive or non-disruptive integrations, respectively.  Inverted LoxP and 
FRT sites flank the gene trap cassette, enabling the orientation to be reversed twice, 
by transiently infecting cells with Cre or Flp recombinase expressing plasmids (double-
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flex system).  The thereby generated isogenic sister clone can be used as a perfect 
internal control.  For the production of retrovirus containing the Cre or Flp expressing 
vector the Cre/Flp-expressing plasmid should be linked with a selection marker (e. g. 
mCherry; Cre-puro), to evaluate infection efficiency and/or select for infected cells.  
CRITICAL  Before infection the ESCs should be propagated by standard procedures 
and should be passaged several times prior to infection and or sorted for haploid 
content if desired.  The maps of these constructs are presented in Supplementary 
Figure 1 and respective sequences in Supplementay Data. 
1 | 3 - 4h prior to infection seed about 250,000 cells per 6- well or 50,000 cells per 
24 well for infection in triplicates; 
2 | Distribute viral supernatant on ESCs.  Infection efficiency can be increased by 
adding 2µg/ml Polybrene to the culture medium.  Alternatively, if you use a 
frozen virus stock thaw aliquot (on ice) and add media according to previously 
determined dilution factor.  
3 | 8 - 12h post infection exchange media.  Check infection efficiency by flow 
cytometry 48h post infection or change to selection media and select until 
selection control wells are empty (e.g. with puromycin it takes 2-3 days).  
4 | Confirm the successful inversion of the gene trap cassette by PCR or western-
blot for the target gene.  
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Box 5 Transposon mutagenesis in haploid ES cells 
Timing: 10 to 15 days  
Various vectors can be used to stably integrate gene trap cassettes into genomic DNA 
of haploid cells.  Amongst them, virus is most commonly used.  However, integration 
sites for viral integrations cluster strongly and thus result in poor genome saturation42.  
Moreover, integration sites relative to gene bodies vary for different vector systems.  
Transposon mutagenesis is an attractive alternative method to integrate gene trap 
vectors into genomes as it not only achieves better genome saturation but also 
circumvents virus work and associated risks. 
Single transposon integrations are only generated by strongly compromising on 
integration efficiency.  When electroporating for complex library preparation (e.g. to 
generate 50 million independently mutated cells), the experimenter needs to 
electroporate at least 50 independent reactions.  Using Tol2 transposons achieves 
good single integration events at 0.5 µg transposon plasmid and 10 µg transposase 
plasmid, however this may vary depending on transposon system and transposase 
variant, electroporator, cell line, and media conditions. 
The challenge for transposon mutagenesis is to achieve single integration events for 
each cell.  Electroporation of DNA is best suited for single integrations, nevertheless 
careful titration of transposon containing plasmids must be undertaken.  The following 
protocol describes one possible approach, namely using an AMAXA 2D electroporator 
(see Equipment) and a Mouse ES cell Nucleofection Kit (see Materials).  The workflow 





• Embryonic Stem Cell NucleofectorTM Kit (or similar), Lonza, mouse (cat. no. 
VPH-1001) or human (cat. no. VAPH-5022). 
• DNeasy Blood & Tissue Kits (50 DNeasy Mini Spin Columns – cat. no. 69504; 
4 DNeasy 96 Plates – cat. no. 69581).  CAUTION  Buffer AL and AL/E: irritant 
if swallowed. Buffer AW1: acutely toxic if swallowed; irritant. Proteinase K: 
acutely toxic if swallowed; health hazard.   
• Isopropanol (AppliChem, Cat. No. A3928.0500PE).  CAUTION  Flammable.  
Irritant if swallowed.  Consult Safety and Hazard sheets that are provided by 
the seller. 
• Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Cat. No. P7589) 
• T4 DNA Ligase (Roche, Cat. No. 10716359001) 
• Phusion High-Fidelity DNA Polymerase (New England Biolabs, Cat. No. 
174M0530S) 
• QIAquick PCR Purification Kit (Qiagen, Cat. No. 28104). Buffer PB  CAUTION  
Flammable.  Irritant if swallowed.  Consult Safety and Hazard sheets that are 
provided by the seller. 
• QIAquick Gel Extraction Kit (Qiagen Cat. No. 28706). Buffer PB  CAUTION  
Flammable. Irritant if swallowed.  Consult Safety and Hazard sheets that are 
provided by the seller. 
• NlaIII - restriction Enzyme (New England Biolabs, Cat. No. R0125S). 
• TaqI - methyltransferase Enzyme (New England Biolabs, Cat. No. M0219S). 
• MseI - restriction Enzyme (New England Biolabs, Cat. No. R0525S). 
• PacI - restriction Enzyme (New England Biolabs, Cat. No. R0547S). 
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• SbfI - restriction Enzyme (New England Biolabs, Cat. No. R0642S). 
• NextSeq 550 v2.5 Reagent Kits (for more details go on www.illumina.com). 
• Tris-HCl 10 mM, pH 8.0 (Teknova, Cat. No. T1173) 
• EDTA Dissodium Salt, 0.005 M (Astral Scientific, Cat. No. E-155-500ML) 
• NaCl 100mM (Jena Bioscience, Cat. No. BU-114-100) 
• Sodium Dodecyl Sulfate 10% (Fisher Bioreagents, Cat. No. BP2436-1)  
CAUTION  Irritant if swallowed.  Causes serious eye damage.  Consult Safety 
and Hazard sheets that are provided by the seller. 
• Proteinase K from Tritirachium album (Sigma, Cat. No. P2308-25MG).  
CAUTION  Irritant if swallowed.  Consult Safety and Hazard sheets that are 
provided by the seller. 
• Agencourt AMPure XP beads (Beckman Coulter; cat. no. #A63882). 
 
Equipment 
• Electroporator (NucleofectorTM 2b Device, Lonza, cat. no. AAB-1001). 
• Covaris Sonicator; 1 × 96 microtube plate, Adaptive Focused Acoustics (AFA) 
fibre (Covaris, cat. no. 520069). 
• Next Generation Sequencer (Illumina NextSeq 550 System or higher; for further 
details go on www.illumina.com).  NGS requires extensive expertise.  We 







• Genomic DNA lysis buffer.  10 mM Tris-HCl, pH 8.0; 5 mM EDTA ;100 mM 
NaCl; 1.0% SDS 1 mg/ml; Proteinase K.  Can be stored at room temperature 
for up to 6 months. 
 
Electroporation of gene traps and screening 
1 | Expand haploid ESCs using standard conditions and sort for haploid cells (Box 
3) a few days prior to electroporation. 
2 | Harvest cells by trypsinization, stop trypsinization using culture medium and 
centrifuge cells using a 15 or 50 ml centrifuge tube depending on cell volume 
for 5 minutes at 20 g. 
3 | In the meantime, prepare electroporation cuvettes and set the electroporator to 
program A-013.  (Alternative programs suggested by the supplier can also be 
tested.) 
4 | Prepare and label cell culture dishes, fill them with ES cell medium. 
5 | Aspirate supernatant, take up cell pellet in 1 x PBS, count cells. 
6 | Add 7 million cells to independent 15 ml centrifuge tubes and fill up with 1 x 
PBS to 15 ml.  Use one tube per planned electroporation plus one tube for 
control. 
7 | Centrifuge cells for 5 minutes at 20 g. In the meantime, prepare DNA solutions. 
8 | In separate 1.5 ml tubes, mix 90 µl of electroporation mix (also see suppliers 
notes), 10 µg of transposase containing plasmid, and various amounts of 
transposon containing plasmid.  We recommend to test (0, 0.25 µg, 0.5 µg, 1 
µg, 2.5 µg, and 5 µg).  Ensure that the total added volume does not exceed 10 
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µl. If the volume is between 10 µl and 20 µl, add 1/9 of the volume of DNA 10 
x PBS.  20 µl should not be exceeded. 
9 | Aspirate 1 x PBS in ES cell containing tubes.  Briefly centrifuge at 100 g for 10-
20 seconds and fully aspirate the 1 x PBS. 
10 | Take up DNA solution and use it to carefully resuspend cell pellet, immediately 
place cells in electroporation cuvette. 
11 | Electroporate cells.  
12 | Carefully aspirate cells from the cuvette using the provided plastic Pasteur 
pipette directly into the cell culture medium of a prepared dish. 
13 | 24 hours post electroporation begin antibiotic selection for integration events. 
Upon completion of selection cells can be used for cryopreservation and 
usage at a later time point. 
 
Library preparation and sequencing 
For library preparation enzyme 1 (E1) is used to fragment the genome (see Table 2).  
Because the recognition sequence for E1 is also present in the terminal repeat of the 
gene trap vector, it is possible to retrieve the exact integration site of the gene trap 
cassette within the genome by circularizing E1-digested genomic DNA (ring ligation) 
and subsequently amplifying the genomic region by inverse PCR (iPCR) using primers 
“US” and “DS” (see Tables below and Supplementary Figure 1b).  To improve iPCR 
efficiency, a linearization step using E2 should be used, which re-opens the rings 
generated previously.  Moreover, each integration site can be mapped by using two 
different E1 enzymes.  We recommend to split the samples and use both E1 enzymes 
on each sample in parallel.  The directionality of the mapping strategies for different 
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gene traps is important, as this affects the assignment of a particular insertion to the 
sense and antisense strand in the genome, respectively.  The DS primer is common 
for all PCR reactions, and binds in the gene trap.  The US primer contains a sequence 
that will bind to the oligo present on the next generation sequencing (NGS) flow cell 
surface, an index of 4 to 8 bases, and then a sequence that binds in the gene trap.  
 
Mutagenesis systems and enzymes used. (EGT; enhanced gene trap): 
Name Enzymes 1 (E1-1; E1-2) Enzyme 2 (E2) Mapping strategy 
Lenti-EGT NlaIII; TaqI PacI 5’ 
Retro-EGT NlaIII; MseI SbfI 5’ 
Tol2-EGT NlaIII; TaqI PacI 3’ 
Tol2-polyA-EGT NlaIII; TaqI PacI 3’ 
 
iPCR primer sequences used for library amplification and sequencing: 
Name Sequence 












The INDEX is a custom barcode (4-8 base pairs) that allows the unique identification 
of all the PCR reactions from one complex sample.  For each sample two different US 
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primers with two different indices need to be used: one for the PCR reaction of the 
genomic DNA digested by E1-1 and one for the PCR reaction of the genomic DNA 
digested by E1-2.  For NGS, all samples can be mixed and loaded into one NGS flow 
cell.  The index sequence will allow the identification of the original samples.  The 
workflow for library preparation is as below. 
1 | Lyse cell pellet according to pellet size in 2-10 ml genomic DNA lysis buffer 
(see REAGENT SET UP). 
2 |  Incubate at 55˚C over night. 
3 | Add 1:1000 RNAse A for 1h at 37˚C. 
4 | Precipitate the genomic DNA using isopropanol and spool the DNA using heat 
sealed Pasteur pipettes. 
5 | Wash with 70% ethanol twice and resuspend in 0,1-2 ml Tris/EDTA - TE Buffer. 
6 | Digest samples with enzymes E1 (Table 2) in parallel (two separate reactions) 
using the following master mix: 
Component   Volume Final concentration 
gDNA 100ng/µl   40 µl  50ng/µl 
10x CutSmart   8 µl  1x 
Enzyme1   3 µl   150U/µl 
dH2O     29 µl 
7 | Incubate at 37˚C (65˚C TaqI) over night. 
8 | Purify restriction digests (Qiagen PCR kit or Agencourt AMPure XP beads). 
9 | Elute in 100 µl in total. 
10 | Perform ring ligation using the following master mix: 
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Component   Volume Final concentration 
E1-gDNA    100 µl  8.3% 
10x Ligation Buffer  120 µl  1x 
T4 DNA Ligase   4 µl  1.6 U/µl 
dH2O    976 µl 
11 | Incubate over night at 16˚C. 
12 | Heat-inactivate T4 DNA Ligase at 65˚C for 15min. 
13 | Linearize samples with enzyme E2 at 37˚C for 2h using the following master 
mix: 
Component   Volume Final concentration 
RL-E1-gDNA   1200 µl  
Enzyme 2    2 µl  ~0.016 U/µl 
14 | Purify restriction digest (Qiagen PCR kit or Magnetic Speedbeads) and elute in 
100 µl H2O in total. 
15 | Perform iPCR reaction.  Use 5-10 reactions per sample and process half or all 
of the digest according to the expected DNA amount.  
Component    Volume Final concentration 
E2-RL-E1-gDNA from step 7 10 µl   20% 
primer US 100 µM   0.1 µl  0.2 µM 
primer DS 100 µM   0.1 µl  0.2 µM 
10 mM dNTP mix   1 µl  0.2 mM 
10x pol. buffer    5 µl   1x 
20x polymerase    3 µl   1.2x 
dH2O     30.8 µl 
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Use the PCR cycler parameters given below: 
Cycles Denature Anneal Extend 
1 95 ºC, 3 min   
2-38 95 ºC, 15 sec 61 ºC, 25 sec 72 ºC, 75 sec 
39   72 ºC, 5 min 
 
CRITICAL  Because after amplification there will be big molar amounts of 
amplicons, there is a very high danger of contaminating other experiments with 
post PCR samples.  We recommend using different pipette sets, rooms and 
equipment for post PCR samples.  
16 | Pool all the PCR products from one sample (5-10 reactions) and analyse 20 µl 
on an agarose gel.  A smear band beginning at around 400 base pairs 
expected. 
17 | Quantify the DNA amount and mix all PCR samples (both separated digests for 
all 5 samples) in a way that you use the same DNA amount from each. 
18 | Load that mixture on another agarose gel and cut the part of the smear between 
400 and 800 base pairs.  
19 | Extract the DNA from the gel using Qiagen’s Gel Extraction Kit.  
20 | Perform next generation sequencing.  
 
Statistical analysis 
To increase reliability of the analysis for each biological replicate two sequencing 
libraries should be constructed: one for sequencing into the adjacent genome 5’ of the 
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insertion site, and one into the 3’adjacent genome.  Pearson correlation should be 
used to compare between the read counts obtained by sequencing the two libraries 
and should allow reliable identification for each insertion.  The statistical analysis can 
be done using the R framework49 to map the reads for each insertion-site and 
Gaussian kernel convolution50 can be used to identify common insertion sites.  By 
using co-occurrence analysis in R and using a Fisher's exact test the overlap of 
common insertion sites across the biological repeats can be performed to identify 
strong gene candidates.  For each gene the insertion sites can be mapped to identify 
position and direction of insertions across the gene body (e.g. gene X).  These 
candidates can be subsequently used for DAVID analysis51 to generate a network of 
genes nodes, with the node sizes being representative of the total number of common 
insertion sites (Figure 6d). 
 
Anticipated results 
Typically, cells will undergo cell division prior to expression of transposase.  Therefore, 
individual colonies appearing in selection will very often be mixed colonies with 
individual cells harboring independent integration events.  Thus, to test for multiplicity 
of infection (MOI), pick colonies, trypsinize cells (of each condition) subsequent to 
completion of selection (days 5-7) and reseed them at clonal density (100 cells/10 cm 
dish, 500 cells/15 cm dish).  Pick 20-50 colonies per condition at day 10-12 after 
reseeding and expand them in 96 well dishes.  Genomic DNA can be prepared in bulk 
or in 96 wells depending on screen set-up using either genomic DNA lysis buffer or 
Quiagen DNeasy Blood & Tissue Kits.  Optionally, acoustic shearing of DNA can be 
carried out using the Covaris system.  It is most convenient to perform a PCR across 
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a random barcode integrated within the transposon and subject it for Sanger 
sequencing.  Clean sequencing tracks are indicative of single integrations, while 
overlaying sequence tracks indicate multiple integration events.  Please note that in 
the presence of transposase, transposons may be remobilized and integrated in a new 
genomic site.  Even though these DNA transposons work via a cut-paste mechanism, 
mobilization in G2 phase of cell cycle can in some cases result in 2 independent 
transposon integration sites within a cell that carry the same random genetic barcode.  
Alternatively perform inverse PCR (iPCR) to map integration sites.  Please note, that 
efficiency of iPCR is only around 80%, so some double integrations may be missed. 
 
For generation of complex pools of cells proceed with screening for phenotypes of 
interest.  Note that loss of protein may take up to 7 to 10 days for stable proteins in 
cases of late integration.  The number and location of integrated transposons per cell 
can be identified by library sequencing and analysis.  Library preparation can be 
performed in various ways (see review by Elling and Penninger 2014 39).  We 
recommend the iPCR method described here and that we have successfully used42.  
Alternatively the transposon insertion site sequencing can be done also by QiSeq 
method as described by MJ Friedrich and collaborators52.   
 
Before executing NGS, please consider the expected complexity.  You will receive 100 
- 200 million reads from one single lane.  As this is usually multiple times more than 
the complexity of your input, you might be oversampling the experiment.  This can – 
by misalignment – cause artefacts.  For that reason, it can be advantageous to 
combine several experiments in 1 lane by indexing.  Subdividing single experiments 
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is not advisable, as the data are not simply additive.  In order to optimally use NGS, 
consider the scale of input and experiment. If you wish to quantitatively use the NGS 
data, the 200 million reads must stem from 200 million independent genomes.  If the 




Figure 1. Workflow diagram of the haploid ESC (hESC) derivation.  (a)  Female 
mice of selected genotypes are selected, superovulated and used for the harvest of 
oocytes.  The oocytes are then activated by the use of strontium chloride (SrCl2) and 
passed through rounds of selection for identification of blastocysts that can be used 
for zona pellucida removal and later transferred individually in NDiff-N2B27/2i/LIF 
culture media in 96 well plates (steps 1 to 52).  (b)  The individual clones are allowed 
to expand to form defined colonies that are disrupted by trypsinisation and grown and 
expanded into individual cell lines (steps 53 to 62).  The established cell lines are then 
quality checked including: haploid status (for cell cycle analysis see Box 1), 
karyotyped (see Box 2), mycoplasma tested and banked.  (c and d)  The haploid cell 
lines can be adapted to DMEM/2i/LIF culture or only DMEM/LIF culture while enriching 
for the haploid content by sorting (see Box 3). 
 
Figure 2. Morphological selection during the haploid ESC (hESC) derivation.  (a)  
On day 4 post harvesting and activation, embryos will be at a variety of developmental 
stages with some embryos looking sub-viable and some lysed (left panel: pre-sort). 
Upon removal of sub-viable or lysed embryos only the embryos that show viable 
characteristics are retained (right panel: post-sort).  Scale bar 250 µm.  (b) On day 5, 
the embryos that have developed to blastocyst and are suitable for zona pellucida 
removal are identified.  Only select embryos that have a well expanded blastocoel for 
zona removal.  Scale bar 250 µm. (c) The check and selection of blastocysts for zona 
removal is repeated on day 6 (representative images).  Scale bar 250 µm.  (d) 
Representative image depicting the morphologic aspect of blastocyst post-zona 
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removal (days 6 to 9). These individual embryos are transferred to 96 well plates at 
this point.  Scale bar 250 µm.  (e) Representative image of a colony that has formed 
from a post-denuding blastocyst and that is ready for dissociation using trypsin.  Scale 
bar 250 µm.  (f) Representative image of an established hESC clone/cell line that is 
ready for quality control.  Scale bar 250 µm. 
 
Figure 3. Representative flow cytometric analysis of the cell cycle profile.  (a)  
The samples harvested and fixed as described in the protocol from Box 2 are acquired 
on SSC-A-Lin versus FSC-A-Lin plot to reveal the ESCs population.  The gate R1 is 
centred around the main population representing the bulk of the ESCs.  (b)  Doublets 
are isolated by setting up gate R2 around the single cells by on an FSC-W-Lin versus 
FSC-A-Lin plot. In the case of the haploid/diploid cells the doublet cell population will 
reveal two overlapping populations, haploid (n; below; note that as explained in the 
text using the right controls this population can be sorted by size only without the use 
of a dye) and diploid (2n; above).  (c)  The live cells are identified by plotting gate R3 
on FSC-W-Lin versus PI to identify and isolate dead cells (left side) and events caused 
by auto-fluorescence (right side).  (d)  Representative cell cycle profile of a clone that 
contains a mix of haploid and diploid cells. On Count-Lin versus PI-Lin axes the 
following cell cycle phases can be identified: the haploid G1 phase of the cell cycle 
(hG1), the haploid S phase of the cell cycle (hS1), the overlapping haploid G2 phase 
of the cell cycle (hG2) and diploid G1 phase of the cell cycle (dG1), the diploid S phase 
of the cell cycle (dS) and the diploid G2 phase of the cell cycle (dG2). 
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Figure 4. Qualitative control of the haploid ESCs.  (a)  Representative examples of 
the cell cycle profiles of three individual ESC cell lines at the first cell cycle analysis 
post derivation. While some clones might be more stable and thus highly enriched for 
haploid ESCs (left side profile), most will be a mix of haploid/diploid cells (middle 
profile) while some will be more unstable and be fully diploid (right side profile).  (b)  
Fluorescent in situ hybridisation analysis of a representative haploid clone shows a 
stable n=20 karyotype (100X magnification). 
 
Figure 5. Sorting of haploid cells. The sorting of the haploid ESCs follows similar 
set-up as for the cell cycle analysis on fixed cells.  (a)  The haploid/diploid cell line is 
stained with Hoechst 33342 and gate R1 is centred around the main population 
representing the bulk of the ESCs (SSC-H-Lin vs. FSC-H-Lin).  (b)  Doublets or clumps 
are removed by setting gate R2 around the main cell population (FL4-W: Hoechst-Lin 
vs. FL4-H: Hoechst-Lin); care must be taken so that diploids are not mistaken as 
doublets. A 1:1 haploid: diploid isogenic mix is recommended to be used always to set 
up the gates.  (c)  The cells gated on R2 are subsequently resolved on an FSC-H-Lin 
vs. FL4-H: Hoechst-Lin plot and haploid G1 (hG1) population is identified and sorted 
using gate R3.  Gate R3 is built tightly around the hG1 peak to avoid sorting of cells 
with lower DNA content (that might be aneuploidy).  (d)  The profile of the hG1 (gate 
R3) on the Count-Lin vs. FL4: Hoechst-Lin representing the cell cycle profile.  (e).  
Graph presenting the overtime %hG1 status of 3 individual WT clones derived by 
individually sorting from the same WT line.  Data was obtained by flow-cytometry 
profiling using PI.  10,000 cells (events) were acquired for each cell line at each time 
point. 
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Figure 6. Representative diagram of a transposon screen in haploid ESCs.  (a)  
Diagram showing a map of one gene trap construct.  The red arrow depicts a random 
integration event into a random gene (Gene X) and points to the direction of 
integration.  As the integration is achieved in haploid ESC, upon diploidization the 
insertion will also be duplicated thus resulting always in homozygous representation.  
In screening strategies using transposons but also CRISPR-Cas9 this represents an 
important advantage.  (b)  Screening using transposon approaches rely on the 
electroporation of the transposon into the haploid ESC and selection of cells that have 
successfully integrated the constructs.  After around 10 days in culture to allow the 
respective proteins to be depleted, these cells can be subsequently used for different 
screening strategies where a comparison between control untreated samples and 
treated sample is made.  We recommend an n=4 technical replicates over 2 biological 
replicates for each group.  (c)  Library preparation for inverse PCR (iPCR) requires 
digestion of the genomic DNA using enzymes E1.  Upon digestion the DNA fragments 
containing part of the enhanced gene trap containing DNA fragments (pEGT; red) are 
ring ligated followed by digestion of the ring DNA constructs containing EGT’s followed 
by next generation sequencing (NGS). See also Supplementary Figure 1b.  (d)  
Schematic representation of a possible screening outcome.  The overlap between the 
common insertion sites across the 4 biological replicates can be represented as a 
Venn diagram.  The enriched transposons (presumably one transposon on each cell) 
can be mapped to the respective genome locations for each gene.  Based on this 
enrichment and based upon statistical analysis across the technical repeats by 
comparing the treatment groups to untreated groups, a gene ranking statistical score 
can be generated.  The top candidate genes can subsequently be used for DAVID 
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pathway analysis for example, where each gene circle size can be representative of 
the number of insertions.  Moreover, mapping the insertions over the gene bodies can 
inform on specific clustering around the promoter or maybe around a relevant domain 
region.  For the statistical analysis see also the protocol by Friedrick et al. 201752. 
 
SI: 
Supplementary Video 1. Removing cumulus oocyte complex from ampulla. 
Supplementary Video 2. Identification and isolation of sub-viable (pathogenic) 
embryos.  
Supplementary Video 3. Zona pellucida removal (denuding) – first 20 seconds. 
Supplementary Video 4. Zona pellucida removal (denuding) – making sure zona is 
gone up to 70  
Supplementary Figure 1  Gene trap vectors and library preparation. 
(a) Schematic representation of the gene trap vectors as presented in Elling et al. 
20171 and on the Haplobank website (www.haplobank.at).  Retroviral enhanced gene 
trap (Retro-EGT; related sequence provided as Supplementary Data file 1).  Lentiviral 
enhanced gene trap (Lenti-EGT; related sequence provided as Supplementary Data 
file 2).  Tol2 autonomous transposon enhanced gene trap (Tol2-EGT; related 
sequence provided as Supplementary Data file 3).  Tol2 autonomous transposon 
polyadenylation enhanced gene trap (Tol2-polyA-EGT; related sequence provided as 
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Supplementary Data file 4).  Abbreviations used:  LTR, long terminal repeat;  6xOPE, 
six osteopontin enhancer elements;  FRT/F3, heterotypic improved flippase target 
sequences;  LoxP/Lox5171, heterotypic target sequences for the Cre-recombinase;  
SA, splice acceptor;  βgal, β-galactosidase;  NeoR, neomycin phosphotransferase 
fusion gene;  polyA, bovine growth hormone polyadenylation sequence;  L200/R175, 
left and right Tol2 transposon elements;  IRES, internal ribosome entry site;  EGFP, 
enhanced green fluorescent protein;  RPB1, DNA-directed RNA polymerase II subunit 
rpb1;  SD, splice donor.  (b)  Schematic representation of library preparation of gene 
trap vectors integration site.  Tol2 – EGT is shown as example.  Following 
fragmentation of the genome with enzyme 1 (E1, NlaIII in the example), the gene trap 
end containing the barcode and a genomic DNA portion is circularized (ring ligation).  
Prior to PCR amplification, linearization with enzyme 2 (E2, PaqI in the example) is 
needed.  Each integration site can be mapped by using two different E1 enzymes.  
The genomic region is then amplified by PCR using US and DS primers. 
 
Supplementary Data:  Four sequences for gene trap cassettes harbouring disruptive 
splice acceptor sites.   
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Table 1:  Troubleshooting guidance. 
 
Step Problem Possible Reason Solution 
26 There are too many embryos 
to easily process in 50-60 
minutes 
More mice superovulated than 
is necessary 
Only superovulate 10-15 mice per session 
27 Embryos are being lost when 
manipulated using a mouth 
pipette 
Pipette tip is flicked against 
cell culture dish 
Use a cell culture dish with low edges or an unpturned dish with drops 
of media 
  
Embryos are sucked up 
beyond the tip of the pipette 
Aspirate a small amount of M2 into the pipette tip and include a small 
air bubble to sit behind the embryos when manipulating 
39 Embryos are not lysed but 
cell division looks abnormal 
Embryo patterning differs in 
the absence of sperm entry 
Allow the embryos to culture for longer 
42 Blastocyst is close to 
breaching it's zona and 
hatching 
The blastocysts were at an 
optimal stage for acid 
treatment over night 
Perform the zona removal, being prepared to take them out of the 
acid sooner 
46 The zona does not dissolve 
rapidly 
The acid Tyrodes is not 
sufficiently warm 
Warm the acid in an incubator at 37 ºC and use a heat plate on the 
microscope 
49 It is hard to visualise the 
dissolving of the zona 
Magnification of the 
microscope is insufficient 
Use x100 magnification capable objective 
50 Zona disappears but then 
reappears when in M2 
Variation in osmotic gradient 
between medias may give the 
impression the zona is 
shrinking away 
Ensure the acid is suitably warmed 
52 Embryos are lost when 
retrieving them from the vial 
Too much media in vial Use no more than 50 µl in the vial.  
 
  
Flush the inner sides and lid of the vial with M2 to dislodge and collect 
embryos that may have got attached to these surfaces 
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Supplementary Figure 1.  (a) Schematic representation of the gene trap vectors as 
presented in Elling et al. 20171 and on the Haplobank website (www.haplobank.at).  
Retroviral enhanced gene trap (Retro-EGT; related sequence provided as 
Supplementary Data file 1).  Lentiviral enhanced gene trap (Lenti-EGT; related 
sequence provided as Supplementary Data file 2).  Tol2 autonomous transposon 
enhanced gene trap (Tol2-EGT; related sequence provided as Supplementary Data 
file 3).  Tol2 autonomous transposon polyadenylation enhanced gene trap (Tol2-
polyA-EGT; related sequence provided as Supplementary Data file 4).  Abbreviations 
used:  LTR, long terminal repeat;  6xOPE, six osteopontin enhancer elements;  
FRT/F3, heterotypic improved flippase target sequences;  LoxP/Lox5171, heterotypic 
target sequences for the Cre-recombinase;  SA, splice acceptor;  βgal, β-
galactosidase;  NeoR, neomycin phosphotransferase fusion gene;  polyA, bovine 
growth hormone polyadenylation sequence;  L200/R175, left and right Tol2 
transposon elements;  IRES, internal ribosome entry site;  EGFP, enhanced green 
fluorescent protein;  RPB1, DNA-directed RNA polymerase II subunit rpb1;  SD, splice 
donor.  (b)  Schematic representation of library preparation of gene trap vectors 
integration site.  Tol2 – EGT is shown as example.  Following fragmentation of the 
genome with enzyme 1 (E1, NlaIII in the example), the gene trap end containing the 
barcode and a genomic DNA portion is circularized (ring ligation).  Prior to PCR 
amplification, linearization with enzyme 2 (E2, PaqI in the example) is needed.  Each 
integration site can be mapped by using two different E1 enzymes.  The genomic 
region is then amplified by PCR using US and DS primers. 
 
 
Supplementary Data file 1.  Sequence file for the retroviral construct (Retro-EGT) 
presented in Supplementary Figure 1a. 
 
Supplementary Data file 2.  Sequence file for the Lentiviral-EGT construct (Lenti-
EGT) presented in Supplementary Figure 1a.  
 
Supplementary Data file 3.  Sequence file for the transposon construct (Tol2-EGT) 
presented in Supplementary Figure 1a. 
 
Supplementary Data file 4.  Sequence file for the transposon construct (Tol2-polyA-
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